17300593

Source:http://linkedlifedata.com/resource/pubmed/id/17300593

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0009429, umls-concept:C0011860, umls-concept:C0030705, umls-concept:C0071097, umls-concept:C0205265, umls-concept:C0332307, umls-concept:C0449432, umls-concept:C0556895, umls-concept:C1179435, umls-concept:C1524073, umls-concept:C1548799, umls-concept:C1555582, umls-concept:C1570906, umls-concept:C1705248, umls-concept:C1707455
pubmed:issue	2
pubmed:dateCreated	2007-2-15
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00101803
pubmed:abstractText	The aim of this study was to compare efficacy and tolerability of initial combination therapy with vildagliptin/pioglitazone to component monotherapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100883645
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adamantane, http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose, http://linkedlifedata.com/resource/pubmed/chemical/DPP4 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl Peptidase 4, http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Lipids, http://linkedlifedata.com/resource/pubmed/chemical/Nitriles, http://linkedlifedata.com/resource/pubmed/chemical/Protease Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines, http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones, http://linkedlifedata.com/resource/pubmed/chemical/pioglitazone, http://linkedlifedata.com/resource/pubmed/chemical/vildagliptin
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1462-8902
pubmed:author	pubmed-author:BaronM AMA, pubmed-author:CamisascaR-PRP, pubmed-author:CouturierAA, pubmed-author:CressierFF, pubmed-author:DejagerSS, pubmed-author:KimS WSW, pubmed-author:RosenstockJJ
pubmed:issnType	Print
pubmed:volume	9
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	175-85
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17300593-Adamantane, pubmed-meshheading:17300593-Adult, pubmed-meshheading:17300593-Blood Glucose, pubmed-meshheading:17300593-Body Weight, pubmed-meshheading:17300593-Diabetes Mellitus, Type 2, pubmed-meshheading:17300593-Dipeptidyl Peptidase 4, pubmed-meshheading:17300593-Dipeptidyl-Peptidase IV Inhibitors, pubmed-meshheading:17300593-Double-Blind Method, pubmed-meshheading:17300593-Drug Therapy, Combination, pubmed-meshheading:17300593-Fasting, pubmed-meshheading:17300593-Female, pubmed-meshheading:17300593-Humans, pubmed-meshheading:17300593-Hypoglycemic Agents, pubmed-meshheading:17300593-Lipids, pubmed-meshheading:17300593-Male, pubmed-meshheading:17300593-Middle Aged, pubmed-meshheading:17300593-Nitriles, pubmed-meshheading:17300593-Protease Inhibitors, pubmed-meshheading:17300593-Pyrrolidines, pubmed-meshheading:17300593-Thiazolidinediones, pubmed-meshheading:17300593-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
pubmed:affiliation	Dallas Diabetes and Endocrine Center, Dallas, TX, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study